A worker leaves the AstraZeneca research facility in Loughborough, March 2, 2010. AstraZeneca is to stop researching some disease areas that form the backbone of its current business -- including schizophrenia and acid reflux -- in a drive to focus R&D efforts and cut costs. In the United States, early-stage discovery research will cease at Wilmington, Delaware, while the Swedish research site in Lund will close, as will the British site at Charnwood, as respiratory and inflammation work moves to Moelndal in Sweden. REUTERS/Darren Staples (BRITAIN - Tags: BUSINESS HEALTH EMPLOYMENT)